Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$LLLI .01976 +.00276 +16.24% Lamperd Less Lethal (LLLI) CMF Pushes Into Positive Territory
Financial Newsweek January 18, 2018
https://finnewsweek.com/lamperd-less-lethal-llli-cmf-pushes-into-positive-territory/742702/
HAON bids moved up. 0003 bout to go
$DATI NEW YORK, Jan. 18, 2018 (GLOBE NEWSWIRE) -- Digital Arts Media Network, Inc. (OTCMKTS:DATI), a specialized tech accelerator leveraging the Public Accelerator-Incubator model, announced that on Saturday, January 13th, 2018, Revenue Republic organized a ‘pop-up’ crypto meetup networking event – CRYPTO MIXER LA – to officially welcome Digital Arts to the cryptocurrency community and to pre-launch upcoming opportunities.https://globenewswire.com/news-release/2018/01/18/1296337/0/en/Digital-Arts-Media-Network-Attends-Revenue-Republic-s-Invitation-only-Cryptocurrency-Networking-Event-As-Guest-Of-Honour.html
EUENF 02, 185k to .20 900% Hit 05 yesterday 500%+
Once launched, EPAZ 's Zenapay Users will see the value of their Bitcoins and Ethereum on the same start screen.
EPAZ
$CHIT - MJ Bitcoin play about to leave trips. Great run about to take place.
$AAPT - will leave trips soon. Major breakout soon!
yes LDSR last 10mil .0008s getting her running shoes laced
NEWS!! $SPI Establishes Strategic Partnership with Hoofoo the Hackproof Cryptocurrency Hardware Wallet https://finance.yahoo.com/news/spi-energy-co-ltd-establishes-110000913.html
*** $FDBL Social Media up 100% ***
### #Blockchain $NQ
#BlockChain - $SPI
$DATI- Revenue Republic is a collective of free-thinking geeks, code monkeys and growth hackers with a single objective; to create digital experiences that have a positive impact on people’s lives.
https://globenewswire.com/news-release/2018/01/18/1296337/0/en/Digital-Arts-Media-Network-Attends-Revenue-Republic-s-Invitation-only-Cryptocurrency-Networking-Event-As-Guest-Of-Honour.html
$DATI Credited with the successful marketing of Centra, Revenue Republic used Saturday’s event as a forum to introduce Xeeda, Inc. (a hardware manufacturer of smartphone crypto wallets) and Blockchain Angels (a new initiative by Manny Fernandez). Both companies have the potential to become clients of Revenue Republic and potential beneficiaries of Digital Arts’ services.
https://globenewswire.com/news-release/2018/01/18/1296337/0/en/Digital-Arts-Media-Network-Attends-Revenue-Republic-s-Invitation-only-Cryptocurrency-Networking-Event-As-Guest-Of-Honour.html
$WCTXF LiCo Energy Metals properties are strategically located in some of the best areas, where the presence of lithium and cobalt has been found historically. LiCo happens to be one of the four companies, in the Atacama Desert in Chile, that holds close to 50% of the world's lithium reserves.
The full featured article can be read on line at: http://metalsnews.com/t1196893i
$rsii..News out.. running over .01 today
LDSR is starting to move up. 0008's going off and 001 not far off.
$GLUU 3.85 rising watch for 3.96 BREAKOUT see chart http://schrts.co/oNPA9b
* * $SPI Breaking out 1.05 +0.18 (20.69%) _BLOCKCHAIN NEWS_
Breaking News from $DATI +1.28% at 1.52
https://finance.yahoo.com/news/digital-arts-media-network-attends-131100310.html
$ISBG Expands Its Global Footprint with 3 Container Order of BESADO Tequila to China
RMRK-Why RMRK?...Read article from August...&...the latest CRYPTO COMPANY 8K & PR
Rimrock Gold Corp (OTCMKTS:RMRK) is probably an early bird in a developing trend. Whenever you get serious buzz in an OTC market space, you get a rash of pivots and reverse mergers. Companies that were never in XYZ business are suddenly either heading in that direction or giving up their tickers to someone else who is. Last year, it was cannabis. This year, it’s cryptocurrency. It’s inevitable. And we don’t for a second mean to disparage the process. Some legitimate top trades spring up from such trends. In any case, it would appear RMRK is the latest such example.
I give you a note from the 10-Q of CRCW (it’s awfully confusing – the company was in the midst of a reverse merger into “The Crypto Company”, and that whole mess is now moving, apparently, into RMRK). Suffice it to say, we are clearly seeing RMRK moving into being “The Crypto Company”, hence the 3 billion shares traded over the past two days, and the 1,900% gains: “Pursuant to a Note Purchase Agreement dated as of March 27, 2017 by and between the Company and Rimrock Gold Corp, (“Rimrock”), the Company agreed to fund up to $300,000 to settle outstanding convertible debt of and accounts payable by and on behalf of Rimrock, for the ultimate acquisition of Rimrock, a currently inactive public company located in Las Vegas, Nevada. The Company expects to consummate the acquisition in the fourth quarter of 2017. For the period from inception to June 30, 2017, the Company advanced $107,000 on behalf of Rimrock to settle the aforementioned liabilities.”
Rimrock Gold Corp (OTCMKTS:RMRK) had trumpeted itself as a Nevada corporation acting as a diversified mineral exploration company focused on identifying, acquiring, advancing, and drilling high-grade Gold-Silver metal exploration projects in Nevada.
However, it would now appear that the ticker is destined to represent The Crypto Company, which is currently understood to be a wholly owned subsidiary of Croefit (CROE), which had been presenting itself as a fitness clothing and apparel company.
Obviously, we are dealing with what amounts to probably the winner of the annual contest for most complicated and convoluted organizational strategy on the planet. But nonetheless, it is also a stock that has exploded higher as it becomes – through however complicated a process – the newest publicly traded player on the crypto playing field.
The proof comes from the note posted above from Croe’s 10-Q, and from this additional note: “On June 7, 2017 (the “Transaction Date”), as a result of the Stock Sale, the Stock Dividend and the Share exchange, each as hereinafter described, (i) The Crypto Company, a Nevada corporation (“Crypto”), became a wholly owned subsidiary of Croe; (ii) all of the former shareholders of Crypto became shareholders of Croe, on a pro-rata basis; and (iii) the operations of Croe solely consisted of the operations of Crypto.”
That leaves this company as the following: “We are developing proprietary technology, including trading management and auditing software, tools and processes, to assist both traditional companies, from start-up businesses to well-established companies, and decentralized autonomous organizations with their design protocol and connect such companies and teams to the resources required to operate and/or trade in cryptocurrencies..”
Recent action has seen 1800% piled on for shareholders of the listing during the trailing month. This is emblematic of the stock. RMRK is a stock who’s past is littered with sudden rips. Furthermore, the name has witnessed a pop in interest, as transaction volume levels have recently pushed approaching 1200% beyond what we have been seeing over the larger time frame.
At this time, carrying a capital value in the market of $1,56M, RMRK, as an entity prior to this transaction, had virtually no reported cash on the books, balanced by about $293K in total current liabilities. That said, that may no longer be a part of the equation. The most important thing you can say here is that this is a ticker now, it would appear, in the crypto game. Hence, you know we will be hot on its tail going forward. For continuing coverage on shares of $RMRK stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next breakout pick!
Disclosure: We hold no position in $RMRK, either long or short, and we have not been compensated for this article.
Sign Up for our 100% FREE Oracle Dispatch Newsletter
01/16/18 8K
https://www.otcmarkets.com/edgar/GetFilingPdf?FilingID=12478056
01/17/18 PR
https://finance.yahoo.com/news/crypto-company-seals-deal-leading-201040190.html;_ylc=X1MDMTE5Nzc4NDE4NQRfZXgDMQRfeXJpZAMxdDFmdXRwZDYxOGJrBGcDZFhWcFpEeHVjejR5TURNMVpXWmxZaTFpWmpNd0xUTTRObUl0T0RObU55MWlNV1l5Wm1JMU5UbG1PRFYxZFdsa1BHNXpQa05TUTFjPQ0KBGxhbmcDZW4tVVMEb3JpZ19sYW5nA2VuBG9yaWdfcmVnaW9uA1VTBHBvcwMwBHJlZ2lvbgNVUwRzeW1ib2wDQ1JDVw--?.tsrc=applewf
RMRK 08/24/17 PR
https://oracledispatch.com/2017/08/24/rimrock-gold-corp-otcmktsrmrk-explodes-higher-crypto-deal-rumors/
$SDVI (+33.33%) Joint Venture Announced!!!
$SDVI Signature Devices Announces Joint Venture with Genius Ventures to launch an Artificial Intelligence CryptoCurrency for GPU Media Devices http://ow.ly/mYV930hRh1d
LDSR strong start here let leave trip ZZZ land today
IFXY merger filings out! Blockchain, crypto and MJ -- name change and share reduction coming soon...
$$$ Holding for silver!!! $$$
$ISBG Expands Its Global Footprint with 3 Container Order of BESADO Tequila to China http://ow.ly/NY5z30hRePL
NQ Mobile Inc. NYSE NQ Stock Announced Establishment of Integration of AI and Blockchain Applications and Technology Architecture
$EPAZ news is out! Epazz ZenaPay Bitcoin Wallet Has Been Downloaded more than 10,000 Times Since Launch on Play Store http://www.otcmarkets.com/stock/EPAZ/news/Epazz-ZenaPay-Bitcoin-Wallet-Has-Been-Downloaded-more-than-10-000-Times-Since-Launch-on-Play-Store?id=180644&b=y
$IFXY Infrax Systems (IFXY) Merges with Cryptocurrency Corp – Cryptocurrency Corp to Invest in Crypto Assets, Provide Blockchain Technology Consulting & ICO Services
Saint Petersburg, FL, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Infrax Systems (OTC:IFXY), a global provider of Internet of Things, Blockchain development and ICO consulting, announces today that on November 7, 2017, Infrax implemented a holding company reorganization pursuant to the Agreement and Plan of Merger (the “Merger Agreement”), dated as of November 1, 2017, among Infrax, Crypto and Crypto SUB Inc., a Nevada corporation (“Merger Sub”), which resulted in Crypto owning all of the outstanding capital stock of Infrax. Pursuant to the Crypto Merger, Merger Sub, a direct, wholly owned subsidiary of Crypto and an indirect, wholly owned subsidiary of Infrax, merged with and into Infrax, with Infrax surviving as a direct, wholly owned subsidiary of Crypto. Each share of each class of Infrax stock issued and outstanding immediately prior to the Crypto Merger automatically converted into an equivalent corresponding share of Crypto stock, having the same designations, rights, powers and preferences and the qualifications, limitations and restrictions as the corresponding share of Infrax stock being converted. Accordingly, upon consummation of the Crypto Merger, Infrax’s stockholders immediately prior to the consummation of the Crypto Merger became stockholders of Crypto. The stockholders of Infrax will not recognize gain or loss for U.S. federal income tax purposes upon the conversion of their shares in the Crypto Merger.
The Crypto Merger was conducted pursuant to NRS 92A.180, 92A.200, NRS 92A.230 and NRS 92A.250 of the General Corporation Law of the State of Nevada (the “MCED”), which provides for the formation of a holding company without a vote of the stockholders of the constituent corporation. The conversion of stock occurred automatically without an exchange of stock certificates. After the Crypto Merger, unless exchanged, stock certificates that previously represented shares of a class of Infrax stock now represent the same number of shares of the corresponding class of Crypto stock. Following the consummation of the Crypto Merger, Crypto Class A shares continue to trade on the OTC Market on an uninterrupted basis under the symbol “IFXY” until the new symbol change is in effect by FINRA and respectively with new CUSIP numbers (for Crypto Class A shares). Immediately after consummation of the Crypto Merger, Crypto will be, on a consolidated basis, a cryptocurrency and blockchain investor and developer. As a result of the Crypto Merger, Crypto became the successor issuer to Infrax and Infrax will become a private subsidiary of Cryptocurrency Corp.
Upon consummation of the Crypto Merger, each share of each class of Infrax stock issued and outstanding immediately prior to the Crypto Merger automatically converted into an equivalent corresponding share of Crypto stock, having the same designations, rights, powers and preferences and the qualifications, limitations and restrictions as the corresponding share of Infrax stock that was converted.
Post merger and name change, Cryptocurrency Corp to invest in Crypto assets, provide blockchain technology consulting and ICO services. Currently, the Company has signed contract with three companies on ICO consulting and services, as combined, raising millions of dollars in funds.
Contact
info@infraxinc.com
http://www.infraxinc.com
Twitter - @ infraxsystems
Facebook - infraxsystems
Source: Infrax Systems
© 2017 GlobeNewswire, Inc.
$DATI Attends Revenue Republic’s Invitation only Cryptocurrency Networking Event As Guest Of Honour
https://finance.yahoo.com/news/digital-arts-media-network-attends-131100310.html
Nice news out for $EPAZ - Epazz ZenaPay Bitcoin Wallet Has Been Downloaded more than 10,000 Times Since Launch on Play Store http://www.otcmarkets.com/stock/EPAZ/news/Epazz-ZenaPay-Bitcoin-Wallet-Has-Been-Downloaded-more-than-10-000-Times-Since-Launch-on-Play-Store?id=180644&b=y
According to rumors from some negotiating firms, DDD could be in contact with CANON to launch a new cryptocurrency, called 3dcoin, the sources do not want to comment, yesterday there were unusual purchases in DDD
The corporation 3D SYSTEMS has been tried but declined to answer
https://es.3dsystems.com/
Thanks MazelTov! Will check KNDI out!
$DATI Digital Arts Media Network Attends Revenue Republic’s Invitation only Cryptocurrency Networking Event As Guest Of Honour
https://finance.yahoo.com/news/digital-arts-media-network-attends-131100310.html
$SPI *SPI Energy Announced Establishment of Blockchain-Based Infrastructure Application Division?
$KNDI >>>> While more than double from its low in 2017, NASDAQ listed, China Based Kandi Technologies (KNDI), China’s “first mover” in the Electric Vehicle (EV) space, is still trading 70% below its 2014 high of $22.49. With Tesla's acquisition of Solar City, KNDI is now the only listed pure-play Electric Vehicle maker available for stock market purchase by US investors. As probably the hottest legitimate technology sector, particularly in China, a logical question by a new investor would be why is KNDI trading so poorly in the hottest Tech Market in history? The likely answer to that has much to do with a comment in my first line as KNDI being a “first-mover” of EVs in China. In this article while it is my intention to help clarify the likely cause of the lethargic trading, but more importantly spell out why KNDI has now crossed the chasm and is set up for a three year run to reach and continue beyond the 200,000 annual EV sales target in 2020 alluded to by Management in last quarters conference call. Very rare is the opening for an investor to have the opportunity to participate in the infancy of a trillion dollar market segment with a proven surviror company with a ten year track record. One thing for sure. As you will see later in this writing, three years from now KNDI will not be a $10-20 stock, nor will it be out of business. It will either still be struggling along at the $5-7 level, or it will be $50 to $100+. The Chairman of this Company is the founder and largest shareholder with around 15 million shares who has never taken a salery over $32,000 a year, never sold a share and bought some $2 million in open market stock over the past year. With most stocks trading at rediculouse and lofty prices, KNDI has to be an interesting speculation even if only for a few hundred shares.
CLSN $2.85 NEWS OUT »»»» Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today provided a year-end 2017 corporate review and announced clinical progress for two of its development programs: ThermoDox®, a proprietary, heat-activated liposomal encapsulation of doxorubicin, which is in Phase III development for treatment of primary liver cancer; and GEN-1, an IL-12 DNA plasmid vector encased in a nanoparticle delivery system, which enables cell transfection followed by persistent, local secretion of the IL-12 protein, and which is in Phase I development for the localized treatment of ovarian cancer.
“In 2017, Celsion achieved our key development goals for our two lead programs, ThermoDox® and GEN-1. We expect to build upon this success in 2018 as we work toward advancing our pipeline of clinical and preclinical development programs, which hold the potential to enhance the power of proven chemotherapy and immunotherapy platforms,” stated Michael H. Tardugno, Celsion's chairman, president and chief executive officer. “After successful and highly efficient financings in the second half of 2017, we have capital sufficient to complete enrollment of our Phase III OPTIMA Study and advance development through the first pre-planned efficacy analysis, which is expected in the first quarter of 2019. We further expect that our current cash position will allow us to make meaningful progress in our open-label, randomized, 86-patient Phase I/II study of GEN-1 in newly diagnosed patients with stage III and IV ovarian cancer. We are well positioned to execute on our clinical development plans to achieve meaningful milestones in the next year, and I look forward to sharing our progress.”
Clinical Developments
ThermoDox®
OPTIMA Study Update. The Company announced that, as of year-end 2017, enrollment in the OPTIMA Study reached 74% of the 550 patients necessary to ensure that its primary endpoint, overall survival, can be evaluated with statistical significance. The OPTIMA Study is currently enrolling at 69 sites in North America, Europe, China and the Asia-Pacific region. The statistical plan for the OPTIMA Study calls for two interim efficacy analyses by the independent Data Monitoring Committee (DMC).
On August 7, 2017, the Company announced that the DMC completed a planned interim analysis of the first 50% of patients randomized in the trial. The DMC unanimously recommended that the OPTIMA Study continue according to protocol to its final data readout, based on the risk-to-benefit analysis conducted by the Committee. The DMC’s role is to review study data at regular intervals, with the primary responsibilities of ensuring the safety of all patients enrolled in the study and monitoring the quality and overall conduct of the trial, including each site's compliance with the minimum radiofrequency ablation (RFA) heating time of 45 minutes specified in the study protocol.
Published HEAT Study Data Support the Phase III OPTIMA Study. A manuscript titled "Phase III HEAT Study Adding Lyso-Thermosensitive Liposomal Doxorubicin to Radiofrequency Ablation in Patients with Unresectable Hepatocellular Carcinoma Lesions," was published in the high impact, peer-reviewed medical journal, Clinical Cancer Research, in November 2017. The article detailed learnings from the Company's 701 patient HEAT Study of ThermoDox® in the treatment of primary liver cancer, including overall survival data from a well-balanced subgroup of 285 patients supporting the OPTIMA Study.
The final overall survival (OS) analysis from the HEAT study demonstrated that in a large, well-bounded subgroup of patients (n=285 patients, 41% of the previous 701 patient HEAT Study), treatment with a combination of ThermoDox® and standardized RFA provided an average 58% improvement in OS compared to standardized RFA alone. The Hazard Ratio (HR) was 0.63 (95% CI 0.43 - 0.93) with a p-value of 0.0198. In this large subgroup, median OS for the ThermoDox® plus standardized RFA group translated into a 25.4-month (more than 2.1 years) survival benefit over the standardized RFA-only group, totaling approximately 80 months (6-1/2 years, which is considered a curative treatment for HCC) for the ThermoDox® plus standardized RFA group, versus 53 months for the standardized RFA-only group.
Conclusions from the publication were further supported by results from a 2016 independent retrospective analysis of the HEAT Study conducted by the National Institutes of Health. The NIH findings are consistent with Celsion's own analysis of the HEAT Study data, which demonstrated that over a 3.5-year period, there was a statistically significant survival benefit in patients treated with ThermoDox® plus optimized RFA over the optimized RFA only group.
R&D Day. Lead investigators (Asia-Pacific and Europe) from the OPTIMA study, representing multiple medical disciplines (hepatology, interventional radiology and surgery), presented their past and current clinical experiences with ThermoDox® as a potential treatment for HCC at a Company-hosted R&D Day event in October 2017.
GEN-1 Immunotherapy
OVATION Study Update. In October 2017, the Company announced completion of enrollment and final clinical and translational research data from its OVATION Study, a Phase Ib dose-escalating clinical trial combining GEN-1, the Company's DNA-based immunotherapy, with the standard of care for the treatment of newly diagnosed patients with advanced Stage III/IV ovarian cancer who will undergo neoadjuvant chemotherapy followed by interval debulking surgery. GEN-1 is an IL-12 DNA plasmid vector formulated as a nanoparticle in a non-viral delivery system to cause the sustained local production and secretion of the Interleukin-12 (IL-12) protein loco-regionally to the tumor site.
The Company further reported encouraging clinical data from the first fourteen patients who completed treatment in the OVATION Study. GEN-1 plus standard chemotherapy produced positive clinical results, with no dose-limiting toxicities and promising dose-dependent efficacy signals, which correlate well with successful surgical outcomes as summarized below:
Of the fourteen patients treated in the entire study, two (2) patients demonstrated a complete response, ten (10) patients demonstrated a partial response and two (2) patients demonstrated stable disease, as measured by RECIST criteria. This translates to a 100% disease control rate ("DCR") and an 86% objective response rate ("ORR"). Of the five patients treated in the highest dose cohort, there was a 100% objective response rate with one (1) complete response and four (4) partial responses.
Fourteen patients had successful resections of their tumors, with nine (9) patients (64%) having an R0 resection, which indicates a microscopically margin-negative resection in which no gross or microscopic tumor remains in the tumor bed. Seven out of eight (87%) patients in the highest two dose cohorts experienced a R0 surgical resection. All five patients treated at the highest dose cohort experienced a R0 surgical resection.
All patients experienced a clinically significant decrease in their CA-125 protein levels as of their most recent study visit. CA-125 is used to monitor certain cancers during and after treatment. CA-125 is present in greater concentrations in ovarian cancer cells than in other cells.
Key translational research findings from all evaluable patients in the study were consistent with the earlier reports from partial analysis of the data and are summarized below:
The intraperitoneal treatment of GEN-1 in conjunction with neoadjuvant chemotherapy resulted in dose-dependent increases in IL-12 and Interferon-gamma (IFN-g) levels that were predominantly in the peritoneal fluid compartment with little to no changes observed in the patients' systemic circulation. These and other post-treatment changes including decreases in VEGF levels in peritoneal fluid are consistent with an IL-12 based immune mechanism.
Consistent with the previous partial reports, the effects observed in the IHC analysis were pronounced decreases in the density of immunosuppressive T-cell signals (Foxp3, PD-1, PDL-1, IDO-1) and increases in CD8+ cells in the tumor microenvironment.
The ratio of CD8+ cells to immunosuppressive cells was increased in approximately 75% of patients, suggesting an overall shift in the tumor microenvironment from immunosuppressive to pro-immune stimulatory following treatment with GEN-1. An increase in CD8+ to immunosuppressive T-cell populations is a leading indicator and believed to be a good predictor of improved overall survival.
These translational research findings demonstrate that GEN-1 in ovarian cancer patients is biologically active and creates a shift in the primary tumor and in the surrounding tumor environment in the peritoneal cavity that promotes a pro-immune T-cell population dynamic and conversion of tumor naïve T-cell into cytotoxic effector T-cells in the tumor microenvironment.
$KCPC GOLDCRYPTO.IO LOW-FLOAT AUX TOKEN LOAD-THE-BOAT! $KCPC https://goldcrypto.io
https://www.keycapitalgroup.com/investors.html
Check out this article on $DATI http://www.thesultansofswingtrading.com/2018/01/digital-arts-media-network-otcmktsdati.html
Followers
|
3286
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2804248
|
Created
|
08/22/10
|
Type
|
Free
|
Moderator Nilbud | |||
Assistants mick ManicTrader PhotoChick Kirimi $Pistol Pete$ |
![]() ![]() ![]() UPDATE; 5-1-22 courtesy of charting /\ wit tweezer top calls /\ Tony @Montana_Trades Really good study sheet on Candlestick Patterns [-chart]pbs.twimg.com/media/FRn8188XMAAdZvk?format=jpg&name=small[/chart] ![]()
![]()
02-07-2021
|
Posts Today
|
0
|
Posts (Total)
|
2804248
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |